These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

255 related items for PubMed ID: 10690558

  • 21. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
    Takiguchi S, Kumazawa E, Shimazoe T, Tohgo A, Kono A.
    Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
    [Abstract] [Full Text] [Related]

  • 22. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice.
    Allegrini G, Goulette FA, Darnowski JW, Calabresi P.
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):261-6. PubMed ID: 14658007
    [Abstract] [Full Text] [Related]

  • 23. Inhibition of cell growth by NB1011 requires high thymidylate synthase levels and correlates with p53, p21, bax, and GADD45 induction.
    Neuteboom ST, Karjian PL, Boyer CR, Beryt M, Pegram M, Wahl GM, Shepard HM.
    Mol Cancer Ther; 2002 Apr; 1(6):377-84. PubMed ID: 12477050
    [Abstract] [Full Text] [Related]

  • 24. Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
    Nanbu T, Umemura N, Ohkoshi E, Nanbu K, Sakagami H, Shimada J.
    Oncol Rep; 2018 Jan; 39(1):367-375. PubMed ID: 29192320
    [Abstract] [Full Text] [Related]

  • 25. Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications.
    Matsui S, Endo W, Wrzosek C, Haridas K, Seetharamulu P, Hausheer FH, Rustum YM.
    Eur J Cancer; 1999 Jun; 35(6):984-93. PubMed ID: 10533483
    [Abstract] [Full Text] [Related]

  • 26. [Absence of cross resistance between an irinotecan plus cisplatin combination and raltitrexed (ZD1694) in two patients with advanced colorectal cancer].
    Sato A, Kurihara M, Matsukawa M, Yamazaki T, Shimada K, Endo W, Yamazaki T, Nakamachi M.
    Gan To Kagaku Ryoho; 2000 Apr; 27(4):617-21. PubMed ID: 10791007
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Topoisomerase I inhibitors in the treatment of head and neck cancer.
    Murphy BA, Cmelak A, Burkey B, Netterville J, Shyr Y, Douglas S, Smith W.
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):47-52. PubMed ID: 11497232
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Chk1 signaling pathways that mediated G(2)M checkpoint in relation to the cellular resistance to the novel topoisomerase I poison BNP1350.
    Yin MB, Hapke G, Wu J, Azrak RG, Frank C, Wrzosek C, Rustum YM.
    Biochem Biophys Res Commun; 2002 Jul 12; 295(2):435-44. PubMed ID: 12150968
    [Abstract] [Full Text] [Related]

  • 33. Combination of raltitrexed with other cytotoxic agents: rationale and preclinical observations.
    Jackman AL, Kimbell R, Ford HE.
    Eur J Cancer; 1999 Mar 12; 35 Suppl 1():S3-8. PubMed ID: 10645207
    [Abstract] [Full Text] [Related]

  • 34. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells.
    Oliver CL, Bauer JA, Wolter KG, Ubell ML, Narayan A, O'Connell KM, Fisher SG, Wang S, Wu X, Ji M, Carey TE, Bradford CR.
    Clin Cancer Res; 2004 Nov 15; 10(22):7757-63. PubMed ID: 15570010
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Potent therapeutic activity of irinotecan (CPT-11) and its schedule dependency in medulloblastoma xenografts in nude mice.
    Vassal G, Boland I, Santos A, Bissery MC, Terrier-Lacombe MJ, Morizet J, Sainte-Rose C, Lellouch-Tubiana A, Kalifa C, Gouyette A.
    Int J Cancer; 1997 Sep 26; 73(1):156-63. PubMed ID: 9334824
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
    McGuire JJ, Magee KJ, Russell CA, Canestrari JM.
    Oncol Res; 1997 Sep 26; 9(3):139-47. PubMed ID: 9220499
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.